Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Acromegaly and Gigantism Therapeutics – Pipeline Assessment and Market Forecasts to 2017Acromegaly and Gigantism Therapeutics Market is Forecast to Show Moderate Growth until 2017
By: Rajesh Gunnam during 2010–2017, the market is expected to record a CAGR of 5%, to reach $1,821m by 2017. The acromegaly and gigantism therapeutics market is expected to grow during forecast period due to expected launch of drugs with novel mechanism of action and newer formulations of existing product at premium price that would increase patient compliance and drive the market growth during the forecast period. Patent of Sandostatin LAR Depot (octreotide) November 2014 and has already been expired in the European countries in July 2010. However, the patent expiration of Sandostatin LAR would have a little effect on the market growth as Sandostatin LAR is biologics, and bio-similar of these drugs would be available at competitive prices provided guidelines for the launch of bio-similars are implemented. Market is expected to show moderate growth due to expected launch of pasireotide LAR (SOM230), which is novel somatostatin analogue with more affinity towards receptors. Also, the expected launch novel formulation of existing products such as octreotide (C2L) implant would help to drive the market growth due to increased patient compliance and increasing number of treated patients. GlobalData analysis suggests that approximately 46% of the global acromegaly and gigantism therapeutics market is unserved. This implies that the acromegaly and gigantism therapeutics market is not well-served by the current products. There is a significant unmet need for a novel, safe and effective therapeutic which can normalize Insulin-like growth factor 1 (IGF) in acromegalic patients. The first line treatment for acromegaly is a surgical resection of adenoma. The relapse after surgical treatment is common approximately 30-40% of cases relapse with disease after surgical treatment. These surgically relapse cases require for further medical therapy. Currently, used drugs in acromegaly offers only moderate efficacy. Sandostatin LAR Depot had effective in controlling tumor size. A strong pipeline will drive the market in the forecast period, with 14 molecules in various phases of pre-clinical and clinical development, including two product extension molecules and one first-in-class molecules in Phase III. One of the Phase III molecules pasireotide has showed better efficacy and safety profile in clinical trial. Pasireotide LAR is second generation somatostatin analogue which has higher affinity to somatostatin receptor subtypes somatostatin 1–3 and somatostatin 5.This makes pasireotide more potential and more effective than currently available octreotide and lanreotide by suppressing of growth hormone secretion. Pipeline candidates provide hope for the acromegaly treatment paradigm. Octreotide implant which is currently in Phase III can deliver octreotide up to six months showed in current studies with no serious side effect observed. Overall octreotide implant results might improve patient compliance, over currently used daily regimen and monthly formulations of octreotide. The significant unmet need can be addressed by drugs in future that have a dosage convenient regimen with better safety and efficacy results as compared to the currently available products in the market for the treatment of acromegaly For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ GlobalData found that the current competition in the acromegaly and gigantism therapeutics market is weak. The weak competition is due to few marketed drugs available for acromegaly. The current product offers only moderate safety and efficacy profile. Only somatostatin analogues showed tumor shrinkage in acromegalic patients. Overall, significant tumor shrinkage was demonstrated in 35% of patients who were on somatostatin analogues. Growth hormone receptor antagonist, Somavert does not showed reduction in tumor shrinkage. Current options available for acromegaly does not completely satisfy the patients’ needs, physicians looking for better treatment options in terms of safety, efficacy and dosage patterns for better compliance. The market scenario expected to change after the launch of pipeline products such as pasireotide LAR, octreotide Implant and octreotide GlobalData, the industry analysis specialist, has released its new report, Acromegaly and Gigantism Therapeutics – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global acromegaly and gigantism therapeutics market. The report identifies the key trends shaping and driving the global acromegaly and gigantism therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global acromegaly and gigantism therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number